Drug that prevents half of breast cancers carries on working
Getty Images
It is already available on the NHS, but researchers at Queen Mary University of London said only a tenth of eligible women were receiving it.Anastrozole can be given only after the menopause because it cannot suppress oestrogen in younger women. "Breast cancer is the commonest cancer in women and continuing to rise very rapidly," Prof Jack Cuzick, the director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London, told the BBC.Isn't this already available?
The academics say this suggests the side-effects are not severe enough to stop women taking the drug.However, a healthy cell does not become cancerous overnight. Instead it goes through multiple mutations that gradually morph it from healthy to cancerous."You're setting the clock back 20 years and you have to start from scratch to develop the cancer, which might take quite a long time," Prof Cuzick told the BBC.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Ex-NBAer Larry Sanders on Juice WRLD Death, Rap Has Serious Drug ProblemLarry Sanders hopes people learn from the tragedy.
Lire la suite »
Opinion: Why you should worry about drug companies' reliance on Chinese ingredientsA U.S. commission recently found that we are 'at risk of exposure to contaminated and dangerous medicines.”
Lire la suite »
Juice WRLD on Feds' Radar Since Private Jet Drug Search in NovemberJuice WRLD's movements have been under the microscope of federal agents since at least last month ...
Lire la suite »
How Trump and the Democrats parted ways on lowering drug pricesThe cost of medicine is a rare bipartisan goal — but impeachment got in the way.
Lire la suite »
Investors fear Pelosi's drug price plan will kill small biotech firmsPrivate equity investors are lobbying against Nancy Pelosi's drug pricing bill, telling her legislative aides the plan would dry up financing for small biotech firms.
Lire la suite »
Labor unions win, drug companies lose in new trade dealThe big winners and losers from the Trump administration’s deal with Democrats on its NAFTA replacement, the U.S.-Mexico-Canada Agreement, are not necessarily the traditional ones
Lire la suite »